Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06415435 · ClinicalTrials.gov registry record · NA
Sylfirm X Radiofrequency Microneedling for the Treatment of Melasma
A NA study of Melasma, sponsored by Benev Company.
- Recruiting
- Registry status
- NA
- Development phase
- 90
- Enrollment target
- 3
- Study locations
NCT06415435: Recruiting NA study of Melasma, sponsored by Benev Company.
NCT06415435 is a NA study of Melasma that is actively recruiting participants, run by Benev Company. The registered enrollment target is 90 participants, above the 34-participant average among 8 other Melasma trials with a reported enrollment target (165% higher). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06415435, a NA study of Melasma, is actively recruiting participants, sponsored by Benev Company.
- RECRUITING
- Registry status
- NA
- Development phase
- 90 participants
- Enrollment target
- 3
- Study locations
Study Summary
Microneedling radiofrequency technology has been shown in clinical studies to improve skin quality, tone, pigment, and to treat various skin conditions related to aging. The purpose of this study is to evaluate efficacy and safety of Sylfrim X device for the treatment of melasma.
Conditions Studied
Interventions
- DEVICE Radiofrequency Microneedling
Study Locations (3)
California
- Scripps Health - La Jolla
North Carolina
- Dermatology, Laser & Vein Specialists of the Carolinas, PLLC - Charlotte
Texas
- Refresh Dermatology - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2023-05-01 |
| Est. Completion | 2024-10-01 |
| Phase | NA |
What NCT06415435 shows while recruiting
NCT06415435 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 90 participants, a relatively small participant target, above the 34-participant average among 8 other Melasma trials with a reported enrollment target (165% higher).
The record links to 1 condition, with Melasma appearing as the primary indexed condition, and to 1 intervention - of which Radiofrequency Microneedling is the first listed.
NCT06415435 reports a single indexed study location in California, North Carolina, Texas.
Frequently Asked Questions
What is clinical trial NCT06415435 about?
NCT06415435 is a clinical study titled "Sylfirm X Radiofrequency Microneedling for the Treatment of Melasma". Microneedling radiofrequency technology has been shown in clinical studies to improve skin quality, tone, pigment, and to treat various skin conditions related to aging. The purpose of this study is to evaluate efficacy and safety of Sylfrim X device for the treatment of melasma.
What is the current status of trial NCT06415435?
This trial is currently recruiting. It is a NA study. The enrollment target is 90 participants. The study started on 2023-05-01. Estimated completion is 2024-10-01.
What conditions does trial NCT06415435 study?
This clinical trial studies the following conditions: Melasma.
What interventions are being tested in trial NCT06415435?
The interventions under investigation include: Radiofrequency Microneedling (DEVICE).
Who is sponsoring clinical trial NCT06415435?
This trial is sponsored by Benev Company, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06415435 being conducted?
This trial has 3 study locations across California, North Carolina, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Melasma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06415435's enrollment target sits among peer trials
90 2nd of 8 the highest of 8 other Melasma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Melasma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
The Use of Image-Based Computer Gradings in the Analysis of Acne, Rosacea, Melasma, and Seborrheic Dermatitis
RECRUITING · NA
-
LaseMD System for the Treatment of Melasma
ACTIVE NOT RECRUITING · NA
-
Efficacy and Safety of PiQo4 Device for Treatment of Melasma
COMPLETED · NA
-
Split-face Study Comparing the Cosmetic Efficacy and Tolerability of Two Topical Products in Participants With Moderate Facial Melasma
COMPLETED · NA
-
A Study of the RevLite Laser System for the Treatment of Refractory Mixed Type Melasma
COMPLETED · NA
-
Salicylic Acid Peels Combined With 4% Hydroquinone in the Treatment of Moderate to Severe Melasma in Hispanic Women
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02521311 · 90 participants · Phase 2
Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)
- NCT02939573 · 90 participants · Phase 2
A Randomized Multicenter Study for Isolated Skin Vasculitis
- NCT03128879 · 90 participants · Phase 2
Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL
- NCT03184038 · 90 participants · NA
Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI